NCT00195533View on ClinicalTrials.gov

Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients

CompletedOBSERVATIONAL
Enrollment

801

Participants

Timeline

Start Date

July 31, 2001

Primary Completion Date

March 31, 2005

Study Completion Date

March 31, 2005

Conditions
Hematological MalignancyLeukemiaMyelodysplasiaLymphomaMyelomaStem Cell Transplantation
Interventions
DRUG

piperacillin-tazobactam

DRUG

glycopeptide

Trial Locations (12)

Unknown

A Coruña

Alcalá de Henares

Alzira

Barcelona

Castellon

Madrid

Salamanca

Santa Cruz de Tenerife

Tarragona

Valencia

Valladolid

Zaragoza

All Listed Sponsors
collaborator

PETHEMA (Program for the Study and Treatment of Haematological Malignances)

UNKNOWN

lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00195533 - Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients | Biotech Hunter | Biotech Hunter